Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Biomaterials. 2021 Oct 13;279:121184. doi: 10.1016/j.biomaterials.2021.121184

Fig. 7. ANCs targeted to T cell-expressed surface receptor increases delivery of NP and NP-encapsulated small molecule cargo to T cells in LNs and blood after locoregional administration.

Fig. 7.

Representative flow cytometry plots (A) and quantification (B-C) of B220- leukocyte association with aCD3- or isotype-ANCs (AlexaFluor488-labeled NP) co-encapsulating Cy5.5 24 h post i.d. injection into flanks of day 6 4T1 tumor-bearing mice (6.25µg total mAb dose, 1µg Cy5.5 dose). B) Total frequency of ANC+ B220- leukocytes [sum of ANC+Cy5.5- and ANC+Cy5.5+ gates in (A)]. C) Total frequency of Cy5.5+ B220- leukocytes [sum of ANC-Cy5.5+ and ANC+Cy5.5+ gates in (A)]. D-E) Quantification of B220+ leukocyte association with aCD3- or isotype-ANCs (AlexaFluor488-labeled NP) co-encapsulating Cy5.5 24 h post i.d. injection into flanks of day 6 4T1 tumor-bearing mice (6.25 µg total mAb dose, 1 µg Cy5.5 dose). Total frequency of total ANC+ (D) or Cy5.5+ (E) B220+ leukocytes quantified as above. Gating controls included LN cells from saline-treated mice. Statistical analyses were done using two-tailed unpaired t-test. **p < 0.01. n.s., not significant.